Clinical trial
Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis…
NCT00057967 · Northwestern University, Other · Completed
Key facts
| NCT number | NCT00057967 |
|---|---|
| Title | Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome |
| Official title | Phase II Trial Of Campath-1H In Patients With Relapsed/Refractory Advanced Mycosis Fungoides or Sezary Syndrome |
| Lead sponsor | Northwestern University, Other |
| Collaborators | Millennium Pharmaceuticals, Inc. Industry Genzyme, a Sanofi Company |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological |
| Interventions | alemtuzumab |
| Enrollment | 37 |
| Start date | Jul 1, 2000 |
| Primary completion | Jun 26, 2007 |
| Completion | Jul 26, 2010 |
| First posted | Apr 9, 2003 |
| Last update posted | Feb 6, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: